ABEONA THERAPEUTICS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
ABEO$2.46-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows for 2024 and 2023
(In thousands)
| For the year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(63,734) | $(54,188) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 2,004 | 2,288 |
| Stock-based compensation expense | 6,628 | 4,768 |
| Change in fair value of warrant and derivative liabilities | 755 | 11,695 |
| Gain on operating lease right-of-use assets | — | (1,065) |
| Accretion and interest on short-term investments | 276 | (93) |
| Amortization of right-of-use lease assets | 903 | 910 |
| Non-cash interest | 1,538 | 417 |
| (Gain) loss on disposal of property and equipment | (2) | 47 |
| Change in operating assets and liabilities: | ||
| Other receivables | 792 | (2,041) |
| Prepaid expenses and other current assets | (564) | (155) |
| Other assets | 181 | (234) |
| Accounts payable and accrued expenses | 1,507 | 2,041 |
| Lease liabilities | (1,315) | (1,196) |
| Change in payable to licensor | (5,000) | — |
| Other current liabilities | 16 | (203) |
| Net cash used in operating activities | (56,015) | (37,009) |
| Cash flows from investing activities: | ||
| Capital expenditures | (2,446) | (331) |
| Proceeds from disposal of property and equipment | 18 | 204 |
| Purchases of short-term investments | (157,010) | (51,636) |
| Proceeds from maturities of short-term investments | 120,198 | 51,971 |
| Net cash (used in) provided by investing activities | (39,240) | 208 |
| Cash flows from financing activities: | ||
| Proceeds from ATM sales of common stock, net of issuance costs | 15,475 | 14,408 |
| Proceeds from sales of common stock under direct placement offering, net of issuance costs | — | 22,981 |
| Payments related to net settlement of restricted share awards | (526) | (182) |
| Proceeds from sales of common stock, net of issuance costs | 70,153 | — |
| Proceeds from issuance of long-term debt | 20,000 | — |
| Payment of debt issuance costs | (963) | (150) |
| Net cash provided by financing activities | 104,139 | 37,057 |
| Net increase in cash, cash equivalents and restricted cash | 8,884 | 256 |
| Cash, cash equivalents and restricted cash at beginning of period | 14,811 | 14,555 |
| Cash, cash equivalents and restricted cash at end of period | $23,695 | $14,811 |
| Supplemental cash flow information: | ||
| Cash and cash equivalents | $23,357 | $14,473 |
| Restricted cash | 338 | 338 |
| Total cash, cash equivalents and restricted cash | $23,695 | $14,811 |
| Supplemental non-cash flow information: | ||
| Right-of-use asset obtained in exchange for new operating lease liabilities | $— | $419 |
| Derivative and warrant additions associated with loan and security agreement | $1,042 | $— |
| Reclassification of derivative liability to equity | $1,135 | $— |
| Changes in accrued property and equipment | $471 | $— |
| Cash paid for interest | $2,670 | $— |
| Cash paid for taxes | $7 | $14 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.